Affimed Announces Pricing of Public Offering of Common Shares
08 November 2019 - 10:30PM
Heidelberg, Germany, November 8, 2019 – Affimed N.V. (“Affimed”
or the “Company”) (Nasdaq: AFMD), a clinical stage
biopharmaceutical company committed to giving patients back their
innate ability to fight cancer, today announced the pricing of its
previously announced public offering of 12,000,000 of its common
shares at a public offering price of $2.50 per common share. In
addition, Affimed has granted the underwriters a 30-day option to
purchase up to an additional 1,800,000 common shares at the public
offering price less underwriting discounts. After deducting the
underwriting discounts, the net proceeds of the public offering are
expected to be approximately $28.2 million. The offering is
expected to close on or about November 13, 2019, subject to
customary closing conditions.
Jefferies LLC and SVB Leerink LLC are acting as joint
book-running managers and SunTrust Robinson Humphrey, Inc. and
Laidlaw & Company (UK) Ltd. as co-managers of the offering. A
shelf registration statement relating to these securities filed
with the Securities and Exchange Commission (the “SEC”) was
declared effective by the SEC on November 7, 2018. The offering
will be made only by means of a prospectus and prospectus
supplement. A preliminary prospectus supplement and accompanying
prospectus related to the offering have been filed with the SEC and
are available at the SEC’s website located at www.sec.gov. A final
prospectus supplement and accompanying prospectus will be filed
with the SEC. Copies of the final prospectus supplement and
accompanying prospectus related to the offering may be obtained by
contacting Jefferies LLC, Attention: Equity Syndicate Prospectus
Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or
by telephone at (877) 821-7388, or by email at
Prospectus_Department@Jefferies.com, or SVB Leerink LLC, Attention:
Syndicate Department, One Federal Street, 37th Floor, Boston, MA
02110, by telephone at (800) 808-7525, ext. 6132, or by email at
syndicate@svbleerink.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of,
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical stage biopharmaceutical
company committed to giving patients back their innate ability to
fight cancer. Affimed’s fit-for-purpose ROCK® platform allows
innate cell engagers to be designed for specific patient
populations. The Company is developing single and combination
therapies to treat hematologic and solid tumors.
Forward-looking Statements
This press release contains forward-looking statements. All
statements other than statements of historical fact are
forward-looking statements, which are often indicated by terms such
as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,”
“intend,” “look forward to,” “may,” “plan,” “potential,” “predict,”
“project,” “should,” “will,” “would” and similar expressions.
Forward-looking statements appear in a number of places throughout
this release and include statements regarding our intentions,
beliefs, projections, outlook, analyses and current expectations
concerning, among other things, the value of our ROCK® platform,
our ongoing and planned preclinical development and clinical
trials, our collaborations and development of our products in
combination with other therapies, the timing of and our ability to
make regulatory filings and obtain and maintain regulatory
approvals for our product candidates our intellectual property
position, our collaboration activities, our ability to develop
commercial functions, expectations regarding clinical trial data,
our results of operations, cash needs, financial condition,
liquidity, prospects, future transactions, growth and strategies,
the industry in which we operate, the trends that may affect the
industry or us and the risks uncertainties and other factors
described under the heading “Risk Factors” in Affimed’s filings
with the SEC. Given these risks, uncertainties and other factors,
you should not place undue reliance on these forward-looking
statements, and we assume no obligation to update these
forward-looking statements, even if new information becomes
available in the future.
Affimed Investor and Media Contact
Gregory Gin, Head of Investor RelationsE-Mail:
IR@affimed.com
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Apr 2024 to May 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From May 2023 to May 2024